Moderna surges 63% YTD on Q1 revenue spike, but Gilead offers steadier cash flow and dividends for long-term investors.

Roivant reports strong trial results and $2.25B Moderna settlement, boosting cash to $4.3B with key drug launches planned in 2026

Roivant announced positive clinical trial results for IMVT-1402 in difficult-to-treat rheumatoid arthritis, showing high response rates at Week 16, and brepocitinib received FDA Breakthrough Therapy Designation for cutaneous sarcoidosis. The company ...